{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T20:59:20Z","timestamp":1775077160789,"version":"3.50.1"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1097\/md.0000000000002364","type":"journal-article","created":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T18:40:24Z","timestamp":1451414424000},"page":"e2364","source":"Crossref","is-referenced-by-count":3,"title":["Stroke Event Rates and the Optimal Antithrombotic Choice of Patients With Paroxysmal Atrial Fibrillation"],"prefix":"10.1097","volume":"94","author":[{"given":"Yicong","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ge","family":"Dang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fubing","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinran","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinsheng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-25-20210309","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1161\/01.CIR.99.23.3028","article-title":"Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study","volume":"99","author":"Levy","year":"1999","journal-title":"Circulation"},{"key":"R2-25-20210309","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"R3-25-20210309","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/archinte.1994.00420130036007","article-title":"Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.","volume":"154","year":"1994","journal-title":"Arch Intern Med"},{"key":"R4-25-20210309","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0002-9343(99)80348-9","article-title":"The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba follow-up study","volume":"98","author":"Krahn","year":"1995","journal-title":"Am J Med"},{"key":"R5-25-20210309","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"Camm","year":"2010","journal-title":"Eur Heart J"},{"key":"R6-25-20210309","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1474-4422(13)70310-7","article-title":"Embolic strokes of undetermined source: the case for a new clinical construct","volume":"13","author":"Hart","year":"2014","journal-title":"Lancet Neurol"},{"key":"R7-25-20210309","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1056\/NEJMoa1311376","article-title":"Atrial fibrillation in patients with cryptogenic stroke","volume":"370","author":"Gladstone","year":"2014","journal-title":"N Engl J Med"},{"key":"R8-25-20210309","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1056\/NEJMoa1313600","article-title":"Cryptogenic stroke and underlying atrial fibrillation","volume":"370","author":"Sanna","year":"2014","journal-title":"N Engl J Med"},{"key":"R9-25-20210309","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1212\/WNL.0b013e31828f1828","article-title":"Incidence of atrial fibrillation detected by implantable loop recorders in unexplained stroke","volume":"80","author":"Cotter","year":"2013","journal-title":"Neurology"},{"key":"R10-25-20210309","first-page":"e257","article-title":"ACC\/AHA\/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society","volume":"114","author":"Fuster","year":"2006","journal-title":"Circulation"},{"key":"R11-25-20210309","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/eurheartj\/ehn599","article-title":"Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation","volume":"31","author":"Friberg","year":"2010","journal-title":"Eur Heart J"},{"key":"R12-25-20210309","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1161\/01.STR.17.4.622","article-title":"Embolic complications in paroxysmal atrial fibrillation","volume":"17","author":"Petersen","year":"1986","journal-title":"Stroke"},{"key":"R13-25-20210309","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2796.2007.01909.x","article-title":"Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation","volume":"264","author":"Lip","year":"2008","journal-title":"J Intern Med"},{"key":"R14-25-20210309","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ijcard.2008.04.050","article-title":"Risk of cardiovascular and cerebrovascular events after atrial fibrillation diagnosis","volume":"136","author":"Ruigomez","year":"2009","journal-title":"Int J Cardiol"},{"key":"R15-25-20210309","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1016\/j.ijcard.2012.06.118","article-title":"Pattern of atrial fibrillation and risk of outcomes: the Loire Valley Atrial Fibrillation Project","volume":"167","author":"Banerjee","year":"2013","journal-title":"Int J Cardiol"},{"key":"R16-25-20210309","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1093\/eurheartj\/eht135","article-title":"Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial","volume":"34","author":"Al-Khatib","year":"2013","journal-title":"Eur Heart J"},{"key":"R17-25-20210309","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/eurheartj\/ehu359","article-title":"Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF trial","volume":"36","author":"Steinberg","year":"2015","journal-title":"Eur Heart J"},{"key":"R18-25-20210309","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/eurheartj\/ehu307","article-title":"Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES","volume":"36","author":"Vanassche","year":"2015","journal-title":"Eur Heart J"},{"key":"R19-25-20210309","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0735-1097(99)00489-1","article-title":"Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy","volume":"35","author":"Hart","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"R20-25-20210309","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/eurheartj\/ehn101","article-title":"Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation?","volume":"29","author":"Nieuwlaat","year":"2008","journal-title":"Eur Heart J"},{"key":"R21-25-20210309","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/j.jacc.2007.07.076","article-title":"Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W substudy","volume":"50","author":"Hohnloser","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R22-25-20210309","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1093\/eurheartj\/eht292","article-title":"The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial","volume":"34","author":"Hohnloser","year":"2013","journal-title":"Eur Heart J"},{"key":"R23-25-20210309","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2261-13-28","article-title":"Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: data from the GISSI-AF trial","volume":"13","author":"Disertori","year":"2013","journal-title":"BMC Cardiovasc Disord"},{"key":"R24-25-20210309","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis","volume":"131","author":"Hart","year":"1999","journal-title":"Ann Intern Med"},{"key":"R25-25-20210309","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1161\/CIR.0b013e31820f14c0","article-title":"2011 ACCF\/AHA\/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"123","author":"Wann","year":"2011","journal-title":"Circulation"},{"key":"R26-25-20210309","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"45","author":"Kernan","year":"2014","journal-title":"Stroke"},{"key":"R27-25-20210309","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"R28-25-20210309","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"R29-25-20210309","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"R30-25-20210309","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"R31-25-20210309","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"R32-25-20210309","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jacc.2011.10.896","article-title":"Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) study","volume":"59","author":"Flaker","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R33-25-20210309","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE\u200aW): a randomised controlled trial","volume":"367","author":"Connolly","year":"2006","journal-title":"Lancet"},{"key":"R34-25-20210309","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"R35-25-20210309","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14841-6","article-title":"Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial","volume":"362","author":"Olsson","year":"2003","journal-title":"Lancet"},{"key":"R36-25-20210309","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jama.293.6.690","article-title":"Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial","volume":"293","author":"Albers","year":"2005","journal-title":"JAMA"},{"key":"R37-25-20210309","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1056\/NEJM199608223350802","article-title":"An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation","volume":"335","author":"Hylek","year":"1996","journal-title":"N Engl J Med"},{"key":"R38-25-20210309","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrcardio.2010.86","article-title":"Challenges in the classification of atrial fibrillation","volume":"7","author":"Lubitz","year":"2010","journal-title":"Nat Rev Cardiol"},{"key":"R39-25-20210309","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1105575","article-title":"Subclinical atrial fibrillation and the risk of stroke","volume":"366","author":"Healey","year":"2012","journal-title":"N Engl J Med"},{"key":"R40-25-20210309","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1161\/01.STR.0000131269.69502.d9","article-title":"Usefulness of ambulatory 7-day ECG monitoring for the detection of atrial fibrillation and flutter after acute stroke and transient ischemic attack","volume":"35","author":"Jabaudon","year":"2004","journal-title":"Stroke"},{"key":"R41-25-20210309","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11739-012-0755-3","article-title":"96\u200ahours ECG monitoring for patients with ischemic cryptogenic stroke or transient ischaemic attack","volume":"9","author":"Manina","year":"2014","journal-title":"Intern Emerg Med"},{"key":"R42-25-20210309","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1161\/STROKEAHA.113.001927","article-title":"Noninvasive cardiac event monitoring to detect atrial fibrillation after ischemic stroke: a randomized, controlled trial","volume":"44","author":"Higgins","year":"2013","journal-title":"Stroke"},{"key":"R43-25-20210309","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1212\/WNL.0b013e3181e0427e","article-title":"Detection of paroxysmal atrial fibrillation with transtelephonic EKG in TIA or stroke patients","volume":"74","author":"Gaillard","year":"2010","journal-title":"Neurology"},{"key":"R44-25-20210309","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jstrokecerebrovasdis.2008.09.005","article-title":"Intermittent atrial fibrillation may account for a large proportion of otherwise cryptogenic stroke: a study of 30-day cardiac event monitors","volume":"18","author":"Elijovich","year":"2009","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"R45-25-20210309","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1001\/jama.288.19.2441","article-title":"Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis","volume":"288","author":"Van Walraven","year":"2002","journal-title":"JAMA"},{"key":"R46-25-20210309","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","article-title":"Effect of clopidogrel added to aspirin in patients with atrial fibrillation.","volume":"360","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000002364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:57:04Z","timestamp":1620961024000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201512280-00025"}},"subtitle":["A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":46,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000002364","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}